Literature DB >> 32216456

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.

Stewart J Tepper1, Messoud Ashina2, Uwe Reuter3, Jan Lewis Brandes4, David Doležil5, Stephen D Silberstein6, Paul Winner7, Feng Zhang8, Sunfa Cheng9, Daniel D Mikol9.   

Abstract

Entities:  

Keywords:  Chronic migraine; efficacy; erenumab; long-term; open-label extension; preventive treatment; safety

Year:  2020        PMID： 32216456     DOI： 10.1177/0333102420912726

Source DB:  PubMed          Journal:  Cephalalgia        ISSN： 0333-1024            Impact factor:   6.292


× No keyword cloud information.
  27 in total

1.  Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.

Authors:  Maria Michela Cainazzo; Carlo Baraldi; Anna Ferrari; Flavia Lo Castro; Luca Pani; Simona Guerzoni
Journal:  Neurol Sci       Date:  2021-02-05       Impact factor: 3.307

2.  First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention.

Authors:  Carl H Göbel; Axel Heinze; Sarah Karstedt; Anna Cirkel; Thomas F Münte; Hartmut Göbel
Journal:  Pain Ther       Date:  2022-07-31

Review 3.  Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.

Authors:  Ann M Murray; Jennifer I Stern; Carrie E Robertson; Chia-Chun Chiang
Journal:  Curr Pain Headache Rep       Date:  2022-09-05

Review 4.  CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies.

Authors:  Yen-Feng Wang; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2022-05-14

5.  Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study.

Authors:  Gaia Pellitteri; Sara Pez; Annacarmen Nilo; Andrea Surcinelli; Gian Luigi Gigli; Christian Lettieri; Mariarosaria Valente
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

6.  Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.

Authors:  Xing Wang; Qiang He; Dingke Wen; Lu Ma; Chao You
Journal:  Neurol Sci       Date:  2021-11-03       Impact factor: 3.830

7.  [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]

Authors:  Till Hamann; Florian Rimmele; Tim Patrick Jürgens
Journal:  Schmerz       Date:  2022-01-18       Impact factor: 1.107

Review 8.  Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.

Authors:  Fred Cohen; Hsiangkuo Yuan; Stephen D Silberstein
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

9.  Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study.

Authors:  Peter J Goadsby; Uwe Reuter; Michel Lanteri-Minet; Gabriel Paiva da Silva Lima; Peggy Hours-Zesiger; Chrystel Fernandes; Shihua Wen; Nadia Tenenbaum; Aditi Kataria; Michel D Ferrari; Jan Klatt
Journal:  Neurology       Date:  2021-04-28       Impact factor: 9.910

10.  Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.

Authors:  Hans Christoph Diener; Peter McAllister; Tim P Jürgens; Yoel Kessler; Xiaoping Ning; Joshua M Cohen; Verena Ramirez Campos; Steve Barash; Stephen D Silberstein
Journal:  Cephalalgia       Date:  2022-03-25       Impact factor: 6.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.